A Double Blind Study for the Treatment of Acute Ulcerative Colitis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety
and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg
mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).